HZNP News and Press, Horizon Therapeutics Public Limited Company From 07/30/22

My portfolio, built specifically for my retirement ~20+ years from now, benefits from a surprise Petrobras gift. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valuable retirement egg. A po...

-- Company Also Makes Fortune Best Workplace for Millennials List for Third Consecutive Year -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named by Seramount (formerly Working Mother media) to its Best Companies for Multicultural Women list. The...

Peak inflation will likely underpin stock market performance in the second half of the year, but at the same time equities are already pricing in a 40% chance of a recession, according to UBS. Looking for better risk/reward, the equities team is getting incrementally defensive by up...

--Thirty global patient advocacy organizations selected to receive financial support to advance programming for rare disease communities -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the 30 patient advocacy organizations selected to receive the inaugural #RA...

Tekla Healthcare has a portfolio, consisting of a variety of well-known biotech and pharmaceutical stocks. Tekla Healthcare is currently trading 4% below NAV. The Tekla CEF may hold up well during this bear market due to the nature of its holdings. If you are a little le...

-- All-Star Ambassador Team Welcomes Mother of NBA Star Kevin Durant to Educate on the Importance of Listening to Your Eyes -- To commemorate Graves’ Disease Awareness Month this July, Horizon Therapeutics plc (Nasdaq: HZNP) is teaming up with all-star patient adv...

The U.S. Food and Drug Administration (FDA) approved Horizon Therapeutics' ( NASDAQ: HZNP ) application seeking expanded approval of Krystexxa (pegloticase) injection for use with immunosuppressant drug methotrexate for uncontrolled gout. Krystexxa was a...

-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to KRYSTEXXA with methotrexate compared to KRYSTEXXA alone -- -- Trial data showed a greater than 30 percentage-point increase in efficacy, and a signif...

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it will release its second-quarter 2022 financial results on Wednesday, Aug. 3, 2022. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s finan...

My portfolio, built specifically for my retirement ~20+ years from now, makes a strong bet on a stock due for potential FDA approval in July. Making monthly contributions, even though they seem small at the time, makes all the difference in the world over time in helping create a valu...